Clinical trial
Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or…
NCT00323362 · Rutgers, The State University of New Jersey, Other · Terminated
Key facts
| NCT number | NCT00323362 |
|---|---|
| Title | Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer |
| Official title | Phase II Study of Imatinib Mesylate and Gemcitabine for Recurrent/Metastatic Non-small Cell Lung Cancer (NSCLC) |
| Lead sponsor | Rutgers, The State University of New Jersey, Other |
| Collaborators | National Cancer Institute (NCI) NIH Novartis Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, imatinib mesylate |
| Enrollment | 17 |
| Start date | Apr 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | May 9, 2006 |
| Last update posted | May 22, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: